PMID- 25185985
OWN - NLM
STAT- MEDLINE
DCOM- 20150526
LR  - 20191113
IS  - 2212-4012 (Electronic)
IS  - 1872-2083 (Linking)
VI  - 8
IP  - 2
DP  - 2014
TI  - Pharmacogenomics in psychiatry: implications for practice.
PG  - 152-9
AB  - Psychotropic medications are used for numerous psychiatric and neurologic 
      disorders, and are associated with in some cases life-threatening adverse 
      effects, high acquisition costs, stringent monitoring requirements, and potential 
      interactions with other medications. Because of the risks of adverse effects and 
      need for adherence, risk mitigation strategies are being implemented to protect 
      consumers. An understanding of receptor activities, cytochrome P450 2D6 and 2C19 
      metabolism, overlapping pharmacology, and polymorphic biomarkers for the dopamine 
      2 D2 receptor gene (DRD2) and dopamine 3 D3 receptor gene (DRD3), serotonin 2A 
      and 2C receptor genes (5HTR2A and 5HTR2C), and human leukocyte antigen (HLA) 
      variants creates opportunities for the integration of pharmacogenomics, and can 
      assist in the application of personalized medicine in this arena. In this review, 
      we discuss the current impression of pharmacogenomic principles pertaining to 
      select psychotropics, with attention given to the atypical antipsychotics, due to 
      their wide use across a broad spectrum of psychiatric disorders (e.g. bipolar 
      disorder, depression, schizophrenia). Patents involving aripiprazole, clozapine, 
      olanzapine, and risperidone will be discussed.
FAU - Moore, Thea R
AU  - Moore TR
FAU - Hill, Angela M
AU  - Hill AM
FAU - Panguluri, Siva K
AU  - Panguluri SK
AD  - Department of Pharmacotherapeutics & Clinical Research, University of South 
      Florida College of Pharmacy, 12901 Bruce B Downs Blvd. MDC 30, Tampa, FL 33612, 
      USA. Tmoore2@health.usf.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Biotechnol
JT  - Recent patents on biotechnology
JID - 101309942
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0 (Receptors, Serotonin, 5-HT2)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
SB  - IM
MH  - Antipsychotic Agents/metabolism/therapeutic use
MH  - Cytochrome P-450 CYP2C19/genetics/metabolism
MH  - Cytochrome P-450 CYP2D6/genetics/metabolism
MH  - Humans
MH  - Mental Disorders/drug therapy/*genetics/pathology
MH  - Patents as Topic
MH  - *Pharmacogenetics
MH  - Receptors, Dopamine D2/genetics/metabolism
MH  - Receptors, Serotonin, 5-HT2/genetics/metabolism
EDAT- 2014/09/05 06:00
MHDA- 2015/05/27 06:00
CRDT- 2014/09/05 06:00
PHST- 2014/05/12 00:00 [received]
PHST- 2014/06/22 00:00 [revised]
PHST- 2014/07/05 00:00 [accepted]
PHST- 2014/09/05 06:00 [entrez]
PHST- 2014/09/05 06:00 [pubmed]
PHST- 2015/05/27 06:00 [medline]
AID - BIOT-EPUB-62157 [pii]
AID - 10.2174/1872208309666140904113615 [doi]
PST - ppublish
SO  - Recent Pat Biotechnol. 2014;8(2):152-9. doi: 10.2174/1872208309666140904113615.